NCT00728000View on ClinicalTrials.gov

Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2010

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

Gemcitabine

Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.

DRUG

Oxaliplatin

100mg/m2 IV on days 1 and 15 given over 120 mins.

DRUG

Erlotinib

100mg/day PO on days 1-14 and 15-28

Trial Locations (1)

45267

University of Cincinnati, Cincinnati

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

University of Cincinnati

OTHER